Program
#AHA24
Late-Breaking Science
Daily Coverage
Industry Highlights
Photo Gallery
Journeys
Previews
#AHA24 Late-Breaking and Featured Science announced
See the impressive lineup of science planned for presentation at Scientific Sessions 2024.
Home
Scientific Sessions 2024
AHA24
Check out these #AHA24 first-time exhibitors
Previews
Register now for Scientific Sessions 2024
Home
Looking ahead to AHA 2024-2025 conferences
AHA23
Watch: Scientific Sessions 2023 Day 2 | Sunday, Nov. 12
AHAtv covers late-breaking science, the Presidential Session and more live from Philadelphia.
AHA23
Getting to the Heart of Stroke™
Deepening the collaboration between neurology and cardiology.
Sponsored
Recurrent Pericarditis Toolkit
Learn the latest from recurrent pericarditis recommendations, including treatment and tapering of initial therapies and significant drug interactions with colchicine.
AHA23
Watch: Scientific Sessions 2023 | Day 1, Saturday, Nov. 11
AHAtv provides full coverage of Day 1's exciting sessions and events.
AHA23
Late-breaking science| Achieving equity in prevention
Health care worker-led trial improves hypertension control, automated pharmacy referral for statin prescribing, SBP levels improving CVD outcomes and reducing hypertension in low-income population.
AHA23
Novel mechanisms for lipid-lowering therapy
Editing the PCSK9 gene, first-in-human trial of lepodisiran, new PCSK9 antibody and statins performance in people with HIV highlight four trials.
Interesting Stories
Sponsored by American Heart Association
Unmet Needs in Hypertension Toolkit
Sponsored by American Heart Association
Recurrent Pericarditis Toolkit
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by American Heart Association
Lp(a) and Peripheral Artery Disease Toolkit
AHA23
Late-breaking science: AI at the bedside
AI-powered stethoscope, speech analysis for HF, interpreting ECGs with AI and prognostic tool for predicting MACE.
AHA23
Shocking decisions in AFib care
Trials’ results highlight the risks and benefits of oral anticoagulation, the superiority of dual direct cardioversion in patients with obesity and the potential for a novel factor XI inhibitor to reduce bleeding in patients with high risk of stroke.
AHA23
Drugs, diet and delivery can optimize hypertension outcomes
Findings evaluate dietary sodium reduction, postpartum blood pressure, an investigational RNA interference therapeutic agent and BP control and dementia risk.
AHA23
Established lecture to present new research developments
Atrial fibrillation experts examine critical needs and potential therapeutic possibilities for the prevalent condition
Tweets by AHAScience
AHA23
Artificial intelligence shows promise and pitfalls
AHA23
Age: Is it a number, or a biology?
AHA23
Scientific Sessions: A meeting of health and hope
AHA23
Teamwork matters
AHA23
Heart failure late-breaking science
AHA23
Changing the course of medicine
AHA23
Your backstage pass to Scientific Sessions 2023
AHA23
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
AHA23
Trials’ results suggest new approaches to reducing CVD risk and symptoms
AHA23
A comprehensive view of cardiogenic shock
AHA23
Metabolic risk factors can complicate kidney, cardiovascular health
AHA23
Q&A With Nobel Laureate Edvard Moser, PhD